Abstract:Cardiovascular disease is the leading cause of mortality in many economically developed nations, and its incidence is increasing at a rapid rate in emerging economies. Diet and lifestyle issues are closely associated with a myriad of cardiovascular disease risk factors including abnormal plasma lipids, hypertension, insulin resistance, diabetes and obesity, suggesting that diet-based approaches may be of benefit. Omega-3 longchain-polyunsaturated fatty acids (ω3 LC-PUFA) are increasingly being used in the prevention and management of several cardiovascular risk factors. Both the ω3 and ω6 PUFA families are considered essential, as the human body is itself unable to synthesize them. The conversion of the two precursor fatty acids - linoleic acid (18:2ω6) and α-linoleic acid (α18:3ω3) - of these two pathways to longer (≥C(20)) PUFA is inefficient. Although there is an abundance of ω6 PUFA in the food supply; in many populations the relative intake of ω3 LC-PUFA is low with health authorities advocating increased consumption. Fish oil, rich in eicosapentaenoic (EPA, 20:5ω3) and docosahexaenoic (DHA, 22:6ω3) acids, has been found to cause a modest reduction in blood pressure at a dose level of >3g/d both in untreated and treated hypertensives. Whilst a multitude of mechanisms may contribute to the blood pressure lowering action of ω3 LC-PUFA, improved vascular endothelial cell function appears to play a central role. Recent studies which evaluated the potential benefits of fish oil in type-2 diabetes have helped to alleviate concerns raised in some previous studies which used relatively large dose (5-8 g/d) and reported a worsening of glycemic control. Several meta-analyses have confirmed that the most consistent action of ω3 LC-PUFA in insulin resistance and type-2 diabetes is the reduction in triglycerides. In some studies, fish oil has been found to cause a small rise in LDL-cholesterol, but a change in the LDL particle size, from the smaller more atherogenic form to the larger, less damaging particle size, have also been noted. ω3 LC-PUFA are effective modulators of the inflammation that accompanies several cardio-metabolic abnormalities. Taking into consideration the pleiotropic nature of their actions, it can be concluded that dietary supplementation with ω3 LC-PUFA will lead to improvements in cardio-metabolic health parameters. These fatty acids pose only minor side effects and more importantly, do not interact adversely with the common drug therapies used in the management and treatment of hypertension, dyslipidemia, type-2 diabetes, and obesity/metabolic syndrome, but in some instances work synergistically, thereby providing additional cardiovascular benefits.

Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence

Omega-3 Polyunsaturated Fatty Acids and Non-Communicable Diseases: Meta-Analysis Based Systematic Review.

Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors

Omega-3 Fatty Acids and Non-Communicable Diseases.

Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcomes in patients with diabetes: A meta-analysis of randomized controlled trials

OMEGA‐3 FATTY ACIDS: THEIR ROLE IN THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS RELATED RISK FACTORS AND COMPLICATIONS

Advances in n-3 polyunsaturated fatty acid nutrition.

Omega-3 fatty acids for cardiovascular event lowering

Omega-3 Polyunsaturated Fatty Acids-Vascular and Cardiac Effects on the Cellular and Molecular Level (Narrative Review)

Omega-3 Fatty Acids and Cardiovascular Disease: New Developments and Applications

Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health

Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues

An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health

Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis

Change Of Plasma Metabolites In Response To Omega-3 Fatty Acids In Chinese Patients With Type 2 Diabetes: A Double-Blinded Randomized Controlled Trial

The Role of Omega- 3 Polyunsaturated Fatty Acids in Diabetes Mellitus Management: A Narrative Review

Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients

Antiatherosclerotic and Antithrombotic Effects of Omega-3 Fatty Acids

Omega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease